{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"infantile-hypertrophic-cardiomyopathy-due-to-mrpl44-deficiency","columns":[{"gene":"","key":"population-cf1ec11c41087bc7c929","label":"Combined oxidative phosphorylation deficiency 16","mondoId":"MONDO:0014162","onsetQualifier":null,"originColumnKey":"MONDO:0014162/OMIM:615395","originalViews":[{"key":"MONDO:0014162/OMIM:615395","label":"Combined oxidative phosphorylation deficiency 16","scopeLabel":"OMIM:615395","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["1516fe3b62d9d815e0fbe11555e73e66fee4e0dc095a02bce1718234f59204c1","1e0f15309a98ff9936cb0a570b1224c9150bf119c3214bc3bd905422df9d9f50","25010b895291529c08a8b8ac2023fa80d0335ef3795d9a5c8fd016d4febef63b","5e1f46ab73c66da44d90b1cec6513cbaa5c7988d1c983e8618fef9faed89cdba","975dfaa66991c3ee11b573f9a04ed031fb6089323459ae23d1926c51b420588f","bf384993b9a74aa02be239c8441cdc8028b19a9aecbdbb40d6ddab3768adb9b6"],"recordQualifiers":{},"scopeLabel":"OMIM:615395","sourceIds":["OMIM:615395"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-cf1ec11c41087bc7c929"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0003688","HP:0031964","HP:0031956","HP:0001639","HP:0002151","HP:0001414"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":6,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":6,"sourceGroups":{"published":6}},"features":[{"hpoId":"HP:0003688","label":"Cytochrome C oxidase-negative muscle fibers","primary":true},{"hpoId":"HP:0031964","label":"Elevated circulating alanine aminotransferase concentration","primary":true},{"hpoId":"HP:0031956","label":"Elevated circulating aspartate aminotransferase concentration","primary":true},{"hpoId":"HP:0001639","label":"Hypertrophic cardiomyopathy","primary":true},{"hpoId":"HP:0002151","label":"Increased circulating lactate concentration","primary":true},{"hpoId":"HP:0001414","label":"Microvesicular hepatic steatosis","primary":true}],"ledeHtml":"Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency is characterized by decreased levels of mitochondrial complexes. The symptoms and signs described include an enlarged heart muscle (hypertrophic cardiomyopathy) and fatty liver (hepatic steatosis), as well as eye problems, headache, paralysis of one side of the body, Leigh-like lesions on brain magnetic resonance imaging (MRI), kidney insufficiency and neurological disease. It is caused by genetic changes in the MRPL44 gene, which results in mitochondrial dysfunction. The cases described seem to be inherited in an autosomal recessive pattern.","mondoId":"MONDO:0014162","node":{"canonicalSlug":"infantile-hypertrophic-cardiomyopathy-due-to-mrpl44-deficiency","comparisons":[{"documentSha256":"0077274a048eccb5fc7825d29e43713b3a8cc06b18c206377a1d07a3dc8a6f12","key":"legacy-infantile-hypertrophic-cardiomyopathy-due-to-mrpl44-deficiency","kind":"legacy","label":"infantile hypertrophic cardiomyopathy due to MRPL44 deficiency","memberIds":["MONDO:0014162"],"mondoId":"MONDO:0014162","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/infantile-hypertrophic-cardiomyopathy-due-to-mrpl44-deficiency.0077274a048eccb5fc7825d29e43713b3a8cc06b18c206377a1d07a3dc8a6f12.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","independentCorroborationEstablished":false,"matchMethod":"automatic-identity-and-attribution","name":"Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency","originalSourceId":"ORPHA:352563","paragraphs":["Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency is characterized by decreased levels of mitochondrial complexes. The symptoms and signs described include an enlarged heart muscle (hypertrophic cardiomyopathy) and fatty liver (hepatic steatosis), as well as eye problems, headache, paralysis of one side of the body, Leigh-like lesions on brain magnetic resonance imaging (MRI), kidney insufficiency and neurological disease. It is caused by genetic changes in the MRPL44 gene, which results in mitochondrial dysfunction. The cases described seem to be inherited in an autosomal recessive pattern."],"rawAttribution":"MONDO:0014162","reviewed":null,"scope":"exact","source":"GARD","sourceRelease":"2026-10-21T17:00:11Z","upstream":"GARD:0012892","url":"https://rarediseases.info.nih.gov/diseases/12892"},"ownColumnKeys":["population-cf1ec11c41087bc7c929"],"publication":"published","relationships":[{"kind":"parent","label":"combined oxidative phosphorylation deficiency","mondoId":"MONDO:0000732","slug":"combined-oxidative-phosphorylation-deficiency"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending"},"records":[{"frequencyKind":"count","key":"1516fe3b62d9d815e0fbe11555e73e66fee4e0dc095a02bce1718234f59204c1","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:615395","disease_name":"Combined oxidative phosphorylation deficiency 16","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0001414","is_excluded":false,"label":"Microvesicular hepatic steatosis","onset_id":null,"reference":"PMID:23315540","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"1e0f15309a98ff9936cb0a570b1224c9150bf119c3214bc3bd905422df9d9f50","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"OMIM:615395","disease_name":"Combined oxidative phosphorylation deficiency 16","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0001639","is_excluded":false,"label":"Hypertrophic cardiomyopathy","onset_id":null,"reference":"PMID:23315540","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"25010b895291529c08a8b8ac2023fa80d0335ef3795d9a5c8fd016d4febef63b","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:615395","disease_name":"Combined oxidative phosphorylation deficiency 16","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0002151","is_excluded":false,"label":"Increased circulating lactate concentration","onset_id":null,"reference":"PMID:23315540","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"5e1f46ab73c66da44d90b1cec6513cbaa5c7988d1c983e8618fef9faed89cdba","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:615395","disease_name":"Combined oxidative phosphorylation deficiency 16","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0031956","is_excluded":false,"label":"Elevated circulating aspartate aminotransferase concentration","onset_id":null,"reference":"PMID:23315540","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"975dfaa66991c3ee11b573f9a04ed031fb6089323459ae23d1926c51b420588f","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:615395","disease_name":"Combined oxidative phosphorylation deficiency 16","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0003688","is_excluded":false,"label":"Cytochrome C oxidase-negative muscle fibers","onset_id":null,"reference":"PMID:23315540","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"bf384993b9a74aa02be239c8441cdc8028b19a9aecbdbb40d6ddab3768adb9b6","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:615395","disease_name":"Combined oxidative phosphorylation deficiency 16","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0031964","is_excluded":false,"label":"Elevated circulating alanine aminotransferase concentration","onset_id":null,"reference":"PMID:23315540","source_release":"2026-06-23"},"sourceGroups":["published"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/12892\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0014162\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-identity-and-attribution</dd><dt>Upstream attribution</dt><dd>GARD:0012892</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency is characterized by decreased levels of mitochondrial complexes. The symptoms and signs described include an enlarged heart muscle (hypertrophic cardiomyopathy) and fatty liver (hepatic steatosis), as well as eye problems, headache, paralysis of one side of the body, Leigh-like lesions on brain magnetic resonance imaging (MRI), kidney insufficiency and neurological disease. It is caused by genetic changes in the MRPL44 gene, which results in mitochondrial dysfunction. The cases described seem to be inherited in an autosomal recessive pattern.</p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/12892\" rel=\"noreferrer\">GARD</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"infantile-hypertrophic-cardiomyopathy-due-to-mrpl44-deficiency","sourceDocuments":[{"name":"GARD: Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency","reviewed":null,"source_release":"2026-10-21T17:00:11Z","url":"https://rarediseases.info.nih.gov/diseases/12892"},{"name":"MONDO: infantile hypertrophic cardiomyopathy due to MRPL44 deficiency","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0014162"}],"sourceNote":"","synonyms":["combined oxidative phosphorylation defect type 16","combined oxidative phosphorylation deficiency 16","combined oxidative phosphorylation deficiency caused by mutation in MRPL44","combined oxidative phosphorylation deficiency type 16","COXPD16","MRPL44 combined oxidative phosphorylation deficiency"],"takeawayHtml":"","title":"infantile hypertrophic cardiomyopathy due to MRPL44 deficiency"},"schemaVersion":1}
